Monomethyl Fumarate
Myeloid Neoplasm
M.D. Anderson Cancer CenterSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
9 Active assets in the Myeloid Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid First Affiliated Hospital of Zhejiang University | Phase 3 | BBB |
Mitoxantrone First Affiliated Hospital of Zhejiang University | Phase 3 | BBB |
Cladribine University of Washington | Phase 2 | BBB |
FILGRASTIM University of Alabama at Birmingham | Phase 2 | BB |
Recombinant Human Granulocyte Colony-Stimulating Factor University of Washington | Phase 2 | BB |
View all 24 →
Same molecule, other indications
Monomethyl Fumarate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →